Prevail Therapeutics

General Information


We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. We are applying a precision medicine approach to neurodegeneration by studying our gene therapies in genetically defined patient populations. We believe this will increase the probability of creating disease-modifying therapies that improve patients’ lives. Our lead program is PR001 for the treatment of Parkinson’s disease with GBA1 mutation, or PD-GBA, and neuronopathic Gaucher disease. We are focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Employees: 43
Founded: 2017
Contact Information
Address 430 East 29th Street, Suite 940, New York, New York 10016, US
Phone Number (917) 336-9310
Web Address
View Prospectus: Prevail Therapeutics
Financial Information
Market Cap $577.9mil
Revenues $0 mil (last 12 months)
Net Income $-25.8 mil (last 12 months)
IPO Profile
Symbol PRVL
Exchange NASDAQ
Shares (millions): 7.4
Price range $17.00 - $17.00
Est. $ Volume $125.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Cowen and Company
CO-Managers Wedbush Securities
Expected To Trade: 6/20/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change